TD Cowen Issues Pessimistic Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its target price lowered by TD Cowen from $30.00 to $20.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “hold” rating on the stock. TD Cowen’s price objective would suggest a potential upside of 16.01% from the company’s current price.

HIMS has been the subject of several other reports. UBS Group set a $32.00 target price on Hims & Hers Health in a report on Tuesday, November 4th. Barclays started coverage on Hims & Hers Health in a research note on Monday, December 8th. They set an “overweight” rating and a $48.00 price objective for the company. Citigroup cut their target price on Hims & Hers Health from $30.00 to $16.50 and set a “sell” rating on the stock in a research note on Monday. BTIG Research lowered their price target on shares of Hims & Hers Health from $85.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Finally, Evercore initiated coverage on shares of Hims & Hers Health in a report on Monday, January 12th. They issued an “in-line” rating and a $33.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have issued a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and an average price target of $39.32.

Hims & Hers Health Trading Down 10.8%

NYSE HIMS opened at $17.24 on Monday. Hims & Hers Health has a one year low of $16.35 and a one year high of $72.98. The company has a 50-day simple moving average of $32.22 and a 200-day simple moving average of $42.77. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The firm has a market capitalization of $3.92 billion, a PE ratio of 31.93, a price-to-earnings-growth ratio of 3.21 and a beta of 2.43.

Hims & Hers Health declared that its board has initiated a stock buyback program on Monday, November 17th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to buy up to 3% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 9,067 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $30.34, for a total value of $275,092.78. Following the completion of the sale, the chief financial officer owned 91,617 shares of the company’s stock, valued at $2,779,659.78. This represents a 9.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $367,870.91. Following the completion of the transaction, the insider owned 169,940 shares of the company’s stock, valued at $6,238,497.40. This represents a 5.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 129,337 shares of company stock valued at $4,651,648. 17.71% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors have recently added to or reduced their stakes in HIMS. Farallon Capital Management LLC boosted its stake in Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after buying an additional 2,533,271 shares in the last quarter. Invesco Ltd. lifted its holdings in Hims & Hers Health by 502.2% in the 2nd quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock valued at $127,237,000 after acquiring an additional 2,128,587 shares during the last quarter. Norges Bank bought a new position in shares of Hims & Hers Health during the 4th quarter valued at about $62,153,000. Clear Street LLC bought a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $83,582,000. Finally, Clear Street Group Inc. acquired a new position in shares of Hims & Hers Health in the 3rd quarter worth approximately $87,372,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers pulled its compounded oral semaglutide offering and said it has held “constructive conversations” with stakeholders — a quick damage‑control move that reduces near‑term regulatory exposure. Hims & Hers is scrapping plan for knockoff Wegovy weight-loss pill. Here’s why
• Positive Sentiment: Some analysts/commentators argue the market is overreacting because GLP‑1 weight‑loss was only a portion of revenue and the company’s broader telehealth platform remains intact. That view supports longer‑term recovery potential if legal/regulatory issues are contained. Hims & Hers Health: Don’t Fall For The Hysteria
• Neutral Sentiment: Some analysts and commentators say the company will survive but warn of a painful reset (“washout”) in the stock while management addresses regulatory/legal fallout. That implies more volatility ahead rather than binary insolvency risk. Hims & Hers Health: The Company Will Survive, But Investors Should Expect A ‘Washout’
• Negative Sentiment: Novo Nordisk filed a U.S. patent lawsuit seeking to block Hims & Hers’ compounded semaglutide products and recover damages — this escalates litigation risk and could lead to injunctions or material liability. Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
• Negative Sentiment: Multiple major outlets report Novo Nordisk’s broader legal offensive and threats that directly target Hims’ GLP‑1 initiative — raising the probability of costly, precedent‑setting litigation. Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections
• Negative Sentiment: The FDA issued a warning letter related to Hims’ activities around compounded GLP‑1 products, which increases regulatory uncertainty and could prompt additional enforcement or restrictions. Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter
• Negative Sentiment: Analysts have trimmed price targets and ratings (Citigroup, TD Cowen, BofA among others) citing higher legal/regulatory risk and revenue uncertainty — a catalyst for further selling pressure. FDA Uncertainty Pushes Analyst To Lower Hims & Hers Forecast
• Negative Sentiment: Shareholder litigation/fraud investigations have been announced, potentially adding legal costs and management distraction. HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation
• Negative Sentiment: Market reaction: heavy volume, steep declines to multi‑month lows and elevated volatility reflect rapid de‑risking by investors; near‑term sentiment will track legal filings and any FDA follow‑ups. Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.